APLLTDNSEAlembic Pharmaceuticals Limited· PharmaceuticalsLowNeutral
Announced Mon, 18 May · 15:52 IST

Chirayu Amin has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Ownership Changes View source PDF

APLLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+3.3%1-day move
₹725.90
prior close
₹728.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.6+0.8+1.0+0.3+3.3+3.2+4.3+4.4+4.6+0.7+1.4+5.2+17.1
Up moveDown movePending
AI summary

Chirayu Amin, along with persons acting in concert (PACs), has submitted a declaration to BSE and NSE confirming that no encumbrance (pledge) was created on Alembic Pharmaceuticals shares during FY 2025-26. The filing lists 34 entities including Alembic Ltd., various Shreno group companies, trusts, and family members as part of the promoter/promoter group. This is a routine regulatory compliance filing under SEBI's substantial acquisition regulations requiring disclosure of share encumbrances by promoters.

Likely market impact

This declaration is neutral to positive for investors as it confirms promoters have not pledged their shares, indicating financial stability and no immediate risk of forced selling from margin calls. The absence of encumbrances means promoters' holding is fully unencumbered.